Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Assets (2019 - 2025)

Keros Therapeutics' Assets history spans 7 years, with the latest figure at $338.0 million for Q4 2025.

  • For Q4 2025, Assets fell 45.12% year-over-year to $338.0 million; the TTM value through Dec 2025 reached $338.0 million, down 45.12%, while the annual FY2025 figure was $338.0 million, 45.12% down from the prior year.
  • Assets reached $338.0 million in Q4 2025 per KROS's latest filing, down from $742.8 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $784.6 million in Q1 2025 to a low of $226.7 million in Q2 2022.
  • Average Assets over 5 years is $410.2 million, with a median of $347.2 million recorded in 2023.
  • Peak YoY movement for Assets: soared 325.35% in 2021, then tumbled 45.12% in 2025.
  • A 5-year view of Assets shows it stood at $255.3 million in 2021, then increased by 20.19% to $306.8 million in 2022, then grew by 20.62% to $370.0 million in 2023, then soared by 66.44% to $615.9 million in 2024, then crashed by 45.12% to $338.0 million in 2025.
  • Per Business Quant, the three most recent readings for KROS's Assets are $338.0 million (Q4 2025), $742.8 million (Q3 2025), and $757.2 million (Q2 2025).